Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
ACQUIRED COMPANY
 
My Lists

BioImagene  Acquired by Roche (2010 $ 100,000,000 )

1601 S. De Anza Blvd., Suite 212
Cupertino, CA 95014
USA
(408) 207-4200
Website Company Summary Management Team
Board

Outside board: (May no longer be on the board) G Steven Burrill (Burrill & Company) Yatin Mundkur (Artiman Ventures Partner) Ajit Singh (Siemens Medical Solutions Division VP) Matthew I Hermann (AHV) Joseph D Keegan (ForteBio President/CEO) John C Dean (SVB Capital Former CEO)
Advisory board: Douglas Sweet (30 years experience in the field of pathology) Ronald Zimmerman (MediGen Group Founder) Robert E Dunkle (Scimagix President/CEO) Roger Hajjar (Spudnik CTO) Sanford Barsky (board certified pathologist) Lila Poonawalla (Quality Circle Forum of India Chairperson)
Former outside board: Ned Ruffin (Venture Law Group (Heller Ehrman));  Mike Schafer (Tullis-Dickerson & Co.);  Ramesh Jain (University of California, San Diego Professor);  Jim Tullis (Tullis-Dickerson & Co. CEO);  Edwin J Lau (ICCP Venture Partners-US Managing Director) Taras Silecky (Ascension Health Ventures) Paul G Lego (Virage CEO) Daniel Green (Dresdner Kleinwort);  Danny Lui (Authosis CEO)
Former advisory board: Micah Siegel (Concept2Company co-Founder) C V K Rao (experience in image processing and pattern matching) Russell Kerschmann (Resolution Sciences) Sarah Bacus (Targeted Molecular Diagnostics CEO);  Edwin Cadman (University of Hawaii Medical School) Bruce Keyt (Abgenix);  Scott Sittler (Solid Tumor Pathology)
Company

Business description: BioImagene is a maker of digital pathology products. BioImagene makes sophisticated bio-image analysis products built on its own technology platform. The products allow pathologists and researchers to analyze and interpret images with greater speed and consistency than with previous methods. BioImagene has successfully applied expertise in the life sciences and information technology to develop innovative applications that overcome the difficulties faced by life science researchers. Our current software suite showcases PATHIAM™ and HistoGrid™. These software systems work with popular assays like IHC, FISH, and H&E, enabling high throughput analysis and accelerated drug discovery. Scimagix™ the leading provider of image informatics solutions for pharmaceutical research and development (R&D). Its flagship SIMS™ (Scientific Image Management System) platform is the first database management system designed to optimize the use of images generated during drug R&D. The Oracle®/Web-based software system is an open architecture platform that enables group- to enterprise-wide image management, providing researchers with a comprehensive and searchable database of image data. The Scimagix Application Suite supports high throughput analysis and mining of image data with its proprietary visual content search technology. This innovative technology dramatically increases the accuracy and productivity of R&D processes by enabling users to select and search based on a specific region of an image, to easily retrieve image sets from diverse experiments based on specific search parameters, to identify correlations, and to gain access to expert data across laboratories and the corporation. Scimagix presently serves eight of the top 15 pharmaceutical companies, including Pfizer Global R&D and Eli Lilly & Co.
Customers include: Eli LillyPfizer;  Institute of Cancer Biology;  UCB Group
Partners include: Advinus Therapeutics ;  Amersham Biosciences;  LigoLab ;  Roche Biosciences;  Spotfire ;  University of Kansas Medical Center
Capital

Rounds: 5
Recent Fundings: Dec 2009   Aug 2008
Capital raised: 95.1M
Last Round: 12.0M
Ownership: Acquired by Roche (2010 $ 100,000,000 )
VCs include: DCM VenturesInvesco Private CapitalSiemens Venture Capital BurrillAndCompanyAuthosis;  Tuputele Ventures;  ICCP Ventures;  Future CapitalArtiman VenturesTullis-DickersonAndCo.;  National Healthcare Services;  Ascension Health Ventures,

Last Tweets


 

Last Mentions


Overview
Record updated: Aug 2010
Sector: Biotech
Headcount: 101-150 as of Aug 2008
Rounds: 5
Recent Fundings: Dec 2009   Aug 2008
Capital Raised: 95.1M
Last Round: 12.0M
Ownership: Acquired by Roche (2010 $ 100,000,000 )